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Edited by Laszlo NagyAbstract INSM1 is a downstream target gene of neurogenin 3
(ngn3). A promoter construct containing the2426/+40 bp region
transiently co-transfected into NIH-3T3 cells with a ngn3
expression plasmid resulted in a 12-fold increase in promoter
activity. The ngn3/E47 heterodimer selectively binds and acti-
vates the E-box3 of the INSM1 promoter. The endogenous
ngn3 and CREB-binding protein (CBP) co-activator occupy
the INSM1 promoter, resulting in hyper-acetylation of histone
H3/H4 chromatin in a human neuroblastoma cell line, IMR-
32. Additionally, adenoviral ngn3 can induce endogenous
INSM-1 expression in pancreatic ductal carcinoma-1 cells
through the recruitment of CBP to the INSM1 promoter and in-
crease the acetylation of the INSM1 promoter region.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transcriptional activation1. Introduction
Both the exocrine and endocrine pancreas develop from a
common multi-potent progenitor cell [1]. During the speciﬁca-
tion of the pancreatic endocrine cells, a complex cascade of
transcription factors must be coordinated to allow proper
development of the four distinct hormone-producing cells (re-
viewed in [2,3]). A key factor in endocrine pancreas speciﬁcation
is the basic helix-loop-helix factor (bHLH) neurogenin 3 (ngn3).
Ngn3 expression is both necessary and suﬃcient to program
undiﬀerentiated progenitor cells to an endocrine cell fate [4–6].
Recently the transcriptional repressor, INSM1, has been
implicated in the cascade of transcription factors essential in
endocrine pancreas development [7]. INSM1 was shown to
be a direct target of ngn3 regulation and required for the dif-
ferentiation of the insulin and glucagon producing cells ofAbbreviations: ngn3, neurogenin 3; INSM1, insulinoma-associated 1;
CAT, chloramphenicol acetyltransferase; ChIP assay, chromatin im-
munoprecipitation assay; PANC-1, pancreatic ductal carcinoma;
EMSA, electrophoretic mobility shift assay; bHLH, basic helix-loop-
helix; CBP, CREB-binding protein
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doi:10.1016/j.febslet.2007.01.087the endocrine pancreas [8]. INSM1 was originally identiﬁed
from an insulinoma subtraction library [9]. Initial expression
analysis revealed expression of INSM1 in tumors of neuroen-
docrine origin [9,10]. Additionally, INSM1 expression was ob-
served in early fetal pancreas [7,8,11] and fetal brain [12,13]
development. Transgenic mouse studies using a 1.7 kb region
of the INSM1 promoter demonstrated early restricted expres-
sion of the INSM1 gene as early as e9.5 in the developing CNS,
olfactory bulb, olfactory neuroepithelium, trigerminal ganglia,
retina neuron, and spinal cord [12]. We identiﬁed NeuroD/b2
as a regulatory protein of the INSM1 promoter [12]. Neu-
roD/b2 is expressed during early pancreas and brain develop-
ment. NeuroD/b2 is activated by ngn3 and persists in the
mature islet cells where it plays a role in maintaining the diﬀer-
entiated state [14] and regulates the expression of insulin [15]
and glucagon [16].
In this study, we investigate the molecular mechanisms
underlying the induction of the INSM1 gene by ngn3. Tran-
sient transfections and EMSA analyses demonstrated speciﬁc
binding of the ngn3/E47 heterodimer on the E-box3 of the
INSM1 promoter. Using chromatin immunoprecipitation
(ChIP) assay, we showed binding of endogenous ngn3 protein
on the INSM1 promoter region. Further, overexpression of
ngn3 protein induced endogenous INSM1 expression in a pan-
creatic ductal carcinoma cell line, PANC-1. Using additional
ChIP assays, we could conclusively demonstrate that the
CREB-binding protein (CBP) co-activator was recruited to
the same INSM1 promoter sequence with a coordinate in-
crease in acetylation both in IMR-32 (endogenous ngn3) and
in Ad-ngn3 infected PANC-1 cells.2. Materials and methods
2.1. Cell culture and transient transfection
NIH-3T3, IMR-32, S-KN-MC, U118MG, U87MG, D283Med,
Daoy, and PANC-1 were maintained in the designated medium as rec-
ommended (ATCC). For transient transfection studies, the cells were
transfected with lipofectamine 2000 reagent (Life Technologies) as
described [12]. Forty-eight hours post-transfection the cells were
collected, lysed and assayed for chloramphenicol acetyltransferase
(CAT) (Promega) activities and normalized with b-galactosidase. All
experiments were repeated at least three times and the average with
the SEM is shown.
2.2. DNA constructs
The 426/+40 bp construct was created by Nhel digestion of the
1661/+40 bp INSM1p-CAT3 construct. The INSM1pDE-box3
CAT construct was prepared as previously described [12]. The E47blished by Elsevier B.V. All rights reserved.
950 M.B. Breslin et al. / FEBS Letters 581 (2007) 949–954expression construct was a kind gift from Dr. Roland Stein (Vanderbilt
University). The pCR3.1b2 (NeuroD/b2 expression vector) construct
was kindly provided by Dr. M.J. Tsai (Baylor College of Medicine).
The pcDNA3-ngn3 construct was generated by PCR ampliﬁcation
from mouse fetal pancreas with sense primer 5 0-GTAAGCTTC-
CAACCGCAGGATGGCGCCTCATCCTT-3 0 and anti-sense primer
5 0-GCGGATCCGTCTCTTCACAAGAAGTCTGAGAACACC-3 0
containing a HindIII or BamHI site (bold) in each primer to enable
cloning into the pcDNA3 expression plasmid (Invitrogen). The mouse
ngn3 cDNA was conﬁrmed by sequencing. The 3X E-box constructs
were created using synthetic oligonucleotides containing three tandem
copies of the individual E-box elements as described [12].2.3. Electrophoretic mobility shift assay (EMSA)
EMSA analysis was performed using a double strand oligonucleo-
tide spanning the 192 to 165 bp region of the INSM1 promoter
(containing E-box3), 5 0 CCCTCAGGTACATCTGCCGCACCTAC-
CG 3 0 and the complementary strand as described [12]. The double
strand oligonucleotide was end-labeled using [c-32P]-ATP (3000
Ci/mmol, NEN) and T4 polynucleotide kinase (New England Biolabs).
E47, NeuroD/b2, and ngn3 proteins were synthesized using the expres-
sion plasmids pcDNA3-ngn3, pCR3.1-NeuroD/b2, and pcDNA3-E47
with the TNT-coupled rabbit reticulocyte lysate kit (Promega). Super-
shift experiments were performed using 1 lg each of mouse anti-ngn3
antibody (Developmental Studies Hybridoma Bank, University of
Iowa), rabbit anti-NeuroD/b2 antibody (Santa Cruz Biotech.), or con-
trol species matched IgG (Southern Biotechnologies). For competition
experiments, 50 or 100 molar excess of cold 3X-E1, 3X-E2, or 3X-E3
oligonucleotide was added along with the labeled oligonucleotide. The
protein–DNA complexes were resolved on a 4% PAGE (40:1) gel. The
gels were dried and exposed to autoradiography.2.4. RT-PCR
Total RNA was isolated from human tumor cells lines, IMR-32, SK-
N-MC (neuroblastoma), U87MG, U118MG (glioblastoma),
D283Med, Daoy (medulloblastoma), and PANC-1 (pancreatic carci-
noma) using Trizol reagent according to manufacturer’s protocol
(Invitrogen). PANC-1 cells were transduced with either AdLacZ or
Ad-ngn3 at an m.o.i. of 100:1 for three days. First-strand cDNA
was prepared from 5 lg of total RNA with the SuperScipt II RT kit
(Invitrogen). One-tenth of the cDNA was used as a template for a
PCR. Human INSM1 primers are (Forward) 5 0-GAGGACCT-
ACTGGCCTTGTA-3 0, (Reverse) 5 0-TCGGATGGGTGGCACTT-3 0
(272 bp); human GAPDH primers are (Forward) 5 0-ACCACAG-
TCCATGCCATCAC-3 0, (Reverse) 5 0-TCCACCACCC-TGTT-
GCTGTA-3 0 (127 bp); mouse ngn3 primers are (Forward)
5 0-TTCGCCCACAACTACATCTG-30, (Reverse) 5 0-CCAGGGAA-
TTCCACCAATGA-30 (200 bp); human ngn3 primers are (Forward)
5 0-GGTAGAAAGGATGACGCCTC-30 and (Reverse) 5 0-CCGAG-
TTGAGGTCGTGCAT-30 (309 bp).2.5. Construction of recombinant adenovirus
Recombinant adenoviruses were generated using the AdEasy XL
adenoviral vector system (Stratagene). Brieﬂy, ngn3 cDNA was sub-
cloned into the pCMV-Shuttle vector as described [17]. To determine
the adenovirus titer, the BD adeno X rapid titer kit was used to stain
the viral infected cells with anti-hexon antibody (BD Biosciences Clon-
tech).2.6. Chromatin immunoprecipitation assay
ChIP assays were performed using either human neuroblastoma,
IMR-32 or adenovirus transduced PANC-1 cells. A ChIP assay kit
(Upstate) was used. The procedures were followed as described previ-
ously [17]. The pre-cleared chromatin was incubated with anti-ngn3
antibody (Developmental Studies Hybridoma Bank, University of
Iowa), anti-CBP (Santa Cruz Biotech.), anti-acetyl-H3, anti-acetyl-
H4 (Upstate) or normal mouse/rabbit IgG (Southern Biotechnology
Associates, Inc) as negative control. The PCR primers used to detect
target sequences were as follows: human INSM1 (Forward) 5 0-ATA-
GAGAAGCAGCAGACCGT-3 0, (Reverse) 5 0-ATTGTTCTCGC-
CTCCCGCTT-3 0. An additional 5 0 upstream INSM1 promoter primer
set was used as a negative control (Forward) 5 0-GAGCTCAAAAGA-
GCAAGGAA-3 0 and (Reverse) 5 0-AGTCATAAGTTGTGATGG-GG-3 0. A small amount of input DNA (2.5%) was used as positive
control. Each ChIP assay was performed at least twice to ensure repro-
ducibility.3. Results and discussion
3.1. Ngn3 activates E-box3 element of the INSM1 promoter
INSM1 is a transcriptional repressor protein whose expres-
sion is limited to early fetal nervous system and fetal pancreas
development [7,8,11–13]. INSM1 expression can be reactivated
in tumors of neuroendocrine origin including insulinoma,
pheochromacytoma, retinoblastoma, medulloblastoma, neuro-
blastoma, medullary thyroid carcinoma, and small cell lung
cancer [9,10]. Tissue-speciﬁc activity of the INSM1 promoter
was demonstrated using a transgenic mouse model with the
1.7 kb human INSM1 upstream region driving expression of
the LacZ gene [12]. Sequential deletion of the promoter region
in vitro revealed the importance of a 500 bp region (426/
+40 bp) for maximal promoter activity [18]. Within this region,
three E-box elements were identiﬁed and E-box3 was shown to
be responsible for approximately 60% of the promoter activity
that was bound and activated by the NeuroD/b2-E47 heterodi-
mer [12]. NeuroD/b2 has a largely overlapping expression pat-
tern with INSM1 during fetal development as well as in tumors
of neuroendocrine origin [12,19]. It was speculated that Neu-
roD/b2 ﬁrst activated INSM1 while INSM1 could counter-reg-
ulate NeuroD/b2 during prenatal pancreas development.
Recently, it was demonstrated that overexpression of adenovi-
ral ngn3 in normal adult duct cells induced the expression of
INSM1 [8]. Therefore, it seems logical to postulate that addi-
tional factors must regulate expression of INSM1. Ngn3
expression precedes expression of NeuroD/b2 in the developing
endocrine pancreas and is a direct regulator of the NeuroD/b2
gene [19]. The sequence of the E-box3 element is also a potential
binding site for the pro-endocrine transcription factor ngn3.
Therefore, we sought to further identify and deﬁne the speciﬁc
INSM1 promoter region responsible for the induction by ngn3.
Transient co-transfection of a 426/+40 bp human INSM1
promoter-CAT construct into NIH-3T3 cells with both ngn3
and E47 expression plasmids caused a 12 fold increase in
the INSM1 promoter-linked reporter activity (Fig. 1A). The
high level of activation may result from the co-expression of
the heterodimer partner, E47. However, addition of E47 alone
only resulted in a modest 2 fold increase in INSM1 promoter
activity (Fig. 1A). Within this region of the INSM1 promoter
there are three potential E-box elements we had previously des-
ignated E-box1, E-box2, and E-box3 from most distal to pro-
ximal. Using chimeric constructs with three tandem copy
repeats of the E-box1, E-box2 or E-box3 upstream of the min-
imal E1bTATA promoter driven CAT reporter, we sought to
demonstrate the E-box(es) responsible for the ngn3 induction.
Co-transfection of the 3X E-box1-E1bTATA CAT construct
with E47 alone or E47/ngn3 combination showed the same level
of induction (25-30 fold) indicating that E47 could bind and
regulate this site (Fig. 1B). Co-transfection of the 3X E-box2-
ElbTATA CAT construct with E47 alone, ngn3 alone, or
E47/ngn3 showed no eﬀect to overall promoter activity
(Fig. 1B). However, transient transfection of the E47/ngn3 het-
erodimer with the 3X E-box3-E1bTATA CAT construct
showed an approximately 120 fold increase in promoter activity
indicating that ngn3/E47 could bind and activate the INSM1
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Fig. 1. Activation of the INSM1 promoter-CAT constructs. (A)
Shown is a schematic diagram of the 426/+40 bp INSM1 promoter-
CAT construct. The three potential E-box elements are shown as open
boxes and indicated as E1, E2, and E3 from most distal to proximal.
NIH-3T3 cells were transfected with the 426/+40 bp INSM1
promoter-CAT reporter construct along with either empty expression
vector (pcDNA3) or equal molar concentrations of E47, ngn3, and/or
NeuroD/b2 expression vectors. Addition of ngn3 and E47 resulted in a
12-fold increase in overall promoter activity. (B) Chimeric constructs
containing three tandem copy repeats of E1, E2, or E3 box from the
INSM1 promoter region were linked to the E1BTATA minimal CAT
reporter constructs. Co-transfection of the individual E-box constructs
with empty expression vector, E47 alone, ngn3 alone, or E47/ngn3 was
performed using NIH-3T3 cells. Shown is the relative fold increase to
CAT activity as compared to control. (C) Comparison of the relative
activity of the wild type promoter and mutant Ebox3 promoter
(INSM1pDE3) construct with E47/ngn3 expression plasmids were
performed in NIH3T3 cells. Deletion of the E-box3 results in a 70%
decrease in INSM1 promoter activity. Co-expression of E47/ngn3 with
the E-box3 deletion promoter construct shows a complete loss of
induction to the promoter activity. Each transfection is repeated at
least three times with the calculated SEM shown. All transfections
were normalized with the internal control b-galactosidase activity.
M.B. Breslin et al. / FEBS Letters 581 (2007) 949–954 951promoter through the E-box3. Additionally, deletion of the
E-box3 element from the 500 bp INSM1 promoter construct re-
sults in an approximately 70% decrease in promoter activity
(Fig. 1C). Further, co-transfection of the E-box3 deletion con-struct with E47/ngn3 expression plasmids shows the loss of acti-
vation to the INSM1 promoter demonstrating the speciﬁcity of
the E47/ngn3 complex for this binding site (Fig. 1C). Therefore,
we have demonstrated that ngn3 and NeuroD/b2 bind to the
same site in the INSM1 promoter region. Transient transfec-
tions demonstrated that ngn3 is a more potent activator (12-
fold verse 5–6-fold) than NeuroD/b2 of INSM1 promoter
activity. Both ngn3 and INSM1 expression is transient during
early fetal development. INSM1 contains a putative INSM1
binding site and can repress its own expression [20]. Although
NeuroD/b2 can bind and activate the INSM1 promoter, it is
not as potent a regulator as Ngn3. Therefore, in the absence
of ngn3, NeuroD/b2 must compete with the negative regulation
exerted by INSM1. Therefore, INSM1 likely overcomes the
induction by NeuroD/b2 and silences its own expression at later
stages of diﬀerentiation.3.2. Ngn3/E47 heterodimer physically binds to the E-box3 of the
INSM1 promoter
In order to conﬁrm the physical association between ngn3
and the E-box3 of the INSM1 promoter region, we performed
an EMSA. E47 alone could bind the E-box3 oligonucleotide
(Fig. 2A, lane 3), ngn3 alone does not bind (Fig. 2A, lane 4)
and the addition of equal amounts of E47 and ngn3 formed a
heterodimer complex on the E-box3 element seen as a faster
migrating complex as compared to the E47 homodimer alone
(Fig. 2A, lane 5 and lane 3). Additionally, E47 and NeuroD/
b2 proteins also form a complex on the same E box element
(Fig. 2A, lanes 7 and 9). Supershift experiments demonstrate
the speciﬁcity of the E47/ngn3 interaction with the E-box3 ele-
ment. Inclusion of an anti-ngn3 antibody results in a ‘‘super-
shift’’ in the migration pattern of the E47/ngn3 complex
(Fig. 2B, lane 3). On the contrary, NeuroD/b2 antibody can
only partially block NeuroD/b2/E47 complex (Fig. 2A, lane
10). In order to demonstrate the relative aﬃnities ngn3 and
NeuroD/b2 have for the E-box3, we performed an EMSA in
the presence of both ngn3 andNeuroD/b2 proteins to determine
if there was a preference for binding of one factor. Equal molar
amounts of E47, ngn3, and NeuroD/b2 protein were incubated
with the E-box3 element and addition of either an anti-ngn3 or
an anti-NeuroD/b2 antibody was used to determine which
protein formed a complex with the E-box3. Addition of an
anti-NeuroD/b2 antibody does not alter the migration of the
complex (Fig. 2B, lane 7). However, inclusion of an anti-ngn3
antibody shows a supershift complex indicating that ngn3 pref-
erentially binds the E-box3 in the presence of equal molar
amounts of NeuroD/b2 protein (Fig. 2B, lane 6). Competition
experiments were performed to demonstrate the speciﬁcity of
the interaction between ngn3 and the E-box3 element. Addition
of either 50 or 100 molar excess cold competitor 3X E-box3 oli-
gonucleotide completely abolishes binding of the ngn3/E47 pro-
tein complex (Fig. 2C). Inclusion of 50 or 100 molar excess of
3X E-box1 or 3X E-box2 cold competitor oligonucleotides does
not diminish the ngn3/E47-3XE-box3 complex demonstrating
that the ngn3 protein interaction with E-box3 is speciﬁc.3.3. Ngn3 occupies and activates the INSM1 promoter through
the recruitment of CBP and hyper-acetylation of histone
H3/H4 in IMR-32 cells
We sought to determine if ngn3 was co-expressed with
INSM1 in selected neuroendocrine tumor cell lines. We used
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in vitro translated protein and an oligonucleotide spanning the192 to
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Fig. 3. RT-PCR analysis of ngn3, GAPDH, and the ChIP analyses of
the endogenous INSM1 promoter. (A) Total RNA was isolated from
human neuroblastoma, IMR-32, SK-N-MC, human glioblastoma cells
U118MG, U87MG, human medulloblastoma, D283Med, and Daoy
using Trizol reagent. Cell lines labeled with * represent the INSM1
expressing cells. IMR-32 cells are positive for ngn3 message. (B) ChIP
analyses were performed using a mouse monoclonal anti-ngn3, anti-
CBP, anti-acetyl H3/H4, or control IgG antibody with chromatin
isolated from IMR-32 cells. Input DNA was included as a positive
control (2.5%) for PCR analysis. The INSM1 promoter region was
immunoprecipitated with anti-ngn3, anti-CBP, and anti-acetyl-H3/H4
antibodies but not negative control IgG. Each ChIP experiment was
repeated to ensure its reproducibility.
952 M.B. Breslin et al. / FEBS Letters 581 (2007) 949–954a small panel of brain tumor cell lines including neuroblastoma
IMR-32 (INSM1 positive), SK-N-MC (INSM1 negative), glio-
blastoma, U87MG and U118MG (INSM1 negative), medullo-
blastoma, D283Med (INSM1 positive) and Daoy (INSM1
negative) for RT-PCR analysis. Ngn3 is expressed in IMR-
32 cells that also co-express INSM1 (Fig. 3A, lane 1). How-
ever, we did not detect ngn3 in D283Med, another INSM1
positive cell line (Fig. 3A, lane 5).
To deﬁnitively demonstrate that ngn3 regulates the INSM1
gene via the E-box3 in the 426/+40 bp promoter region, we
performed a ChIP assay using a mouse ngn3 monoclonal anti-body in IMR-32 cells (both ngn3/INSM1 positive). In the pres-
ence of a ngn3 antibody, the region of the INSM1 promoter
containing the E-box3 was ampliﬁed (Fig. 3B, lane 2). The
same region of the INSM1 promoter was not ampliﬁed with
pre-immune mouse IgG (Fig. 3B, lane 3). Inclusion of a 5 0 up-
stream INSM1 region that did not contain the E-box3 element
was not ampliﬁed further demonstrating the speciﬁcity of the
interaction. Therefore, we showed that endogenous ngn3 pro-
tein occupies the E-box3 containing region of the INSM1 pro-
moter in vivo. The recruitment of co-activators such as p300/
CBP is required by the bHLH proteins to function as tran-
scriptional activators [21,22]. ChIP assays using an anti-CBP
antibody demonstrates the recruitment of CBP to the INSM1
promoter region (Fig. 3B). The co-activator p300/CBP medi-
ates interactions between the DNA binding transcription fac-
tors and the RNA polymerase II transcriptional machinery
to facilitate gene transcription [23]. Both p300/CBP possess
intrinsic acetyltransferase activity and can associate with pro-
teins that possess acetyltransferase activity. Acetylation of his-
tones and other proteins contributes to transcriptional
activation and nucleosomal remodeling that accompanies gene
activation. In IMR-32 cells, we observed the recruitment of
CBP to the INSM1 promoter using anti-CBP antibody. This
M.B. Breslin et al. / FEBS Letters 581 (2007) 949–954 953observation to our knowledge is the ﬁrst demonstration of
ngn3 recruitment of CBP on a bona ﬁde ngn3 target gene.
However, other laboratories have demonstrated the direct
interaction between ngn3 and p300 when using an artiﬁcial
E-box construct [24]. Furthermore, we have demonstrated that
both histone H3 and H4 located at the ngn3 binding region
were hyper-acetylated in IMR-32 cells (Fig. 3C). Accordingly,
these studies enhance our understanding of the modulation of
INSM1 by ngn3.
3.4. Ngn3 induces endogenous INSM1 expression in PANC-1
cells through the recruitment of CBP and hyper-acetylation
of histone H3/H4
During organ speciﬁcation, members of the bHLH tran-
scription factor family are required for organogenesis. In pan-
creas development, a subset of ngn3 positive epithelial cells
commit to the endocrine pathway. Our studies are aimed at
analyzing the molecular mechanisms for induction of INSM1
by ngn3. In order to conﬁrm that ngn3 can regulate INSM1
in vivo, we used adenoviral expression of ngn3 to induce
endogenous expression of INSM1 in human pancreatic ductal
epithelial carcinoma cells, PANC-1. RT-PCR analysis with
non-transduced, Ad-LacZ, or Ad-ngn3 transduced cells clearlyPA
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repeated to ensure its reproducibility.show the induction of INSM1 expression (Fig. 4A, lane 3). Ad-
ngn3 expression was also conﬁrmed in the PANC-1 cells
(Fig. 4A, lane 3). ChIP assay using anti-CBP antibody demon-
strates the recruitment of CBP to the INSM1 promoter region
in the Ad-ngn3 transduced PANC-1 cells in contrast to the Ad-
LacZ transduced PANC-1 cells (Fig. 4B). Further, ChIP assay
was performed to assess the histone acetylation status of the
INSM1 promoter region in the presence of overexpressed
ngn3. Addition of an anti-acetyl-histone H4 antibody and to
a lesser extent anti-acetyl-histone H3 antibody was able to
pull-down the E-box3 containing INSM1 promoter region in
the Ad-ngn3 transduced PANC-1 cells. This region was not
precipitated in the control Ad-LacZ transduced PANC-1 cells
(Fig. 4B and C). Hence, we have conclusively demonstrated
that the mechanism for the regulation of the INSM1 gene by
ngn3 is via binding the E-box3 element present in the human
INSM1 promoter region through the recruitment of the co-
activator CBP with a concomitant increase in acetylation of
histone H3 and H4.
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